Core Viewpoint - The company aims to enhance its refined and intelligent management capabilities in the medical device distribution sector through the implementation of information systems, thereby strengthening its service attributes within the industry chain and promoting product diversification and integration with upstream and downstream partners [1][2]. Group 1: Business Overview - The company, Jianfa Zhixin, operates as a national high-value medical device distributor, focusing on direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to end hospitals [1]. - The company has accumulated extensive operational and service experience in the medical device distribution field, establishing a certain market position through years of development and exploration of industry transformation [1][2]. Group 2: Future Development Plans - The company plans to ensure growth in sales of its core vascular intervention products while expanding sales in IVD, surgical, dental, and ophthalmic medical device sectors to solidify its foundation for scaled development [2]. - The company intends to strengthen collaboration with upstream manufacturers by providing efficient, flat, and centralized professional services across various dimensions such as channel access management, logistics management, inventory management, and information management [2]. - The company aims to explore opportunities in centralized operation management services for public hospital medical consumables, expanding direct sales and centralized operation services, and continuously developing and upgrading its SPD management system [2]. - The company will enhance its existing information systems to improve data analysis and lean management capabilities, providing robust support for business development [2]. Group 3: Financial Overview - The company plans to raise funds through its upcoming IPO to enhance its refined and intelligent management capabilities in medical device distribution, optimize its financial structure, and reduce operational risks [1]. - The company reported a significant increase in net cash flow from operating activities, amounting to 164 million yuan, a year-on-year increase of 539 million yuan [21]. - As of the first half of 2025, the company’s weighted average return on net assets was 8.84%, reflecting a decline of 0.35 percentage points compared to the same period last year [17]. Group 4: Revenue Composition - In 2024, the company's revenue composition included 99.666 billion yuan from vascular intervention, 38.468 billion yuan from surgical instruments, 23.39 billion yuan from IVD, 11.179 billion yuan from medical devices, and 4.997 billion yuan from other medical devices [6]. - The company’s revenue structure for 2023 showed similar trends, with vascular intervention contributing 92.046 billion yuan and surgical instruments contributing 30.7 billion yuan [8]. Group 5: Shareholder Structure - As of June 13, 2025, the largest shareholder of the company was Xiamen Jianfa Medical Health Investment Co., Ltd., holding 51.02% of the shares [51].